Please use this identifier to cite or link to this item:
|Title:||Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells||Authors:||Morgillo, Floriana
Della Corte, Carminia Maria
Mauro, Concetta di
de Vita, Ferdinando
|Keywords:||AKT;breast cancer;ipatasertib;novel drugs;taselisib||Keywords Plus:||AKT INHIBITOR GDC-0068;PIK3CA MUTATIONS;RESISTANCE;PATHWAY;GROWTH;PTEN;PI3K;METAANALYSIS;COMBINATION;METASTASIS||Issue Date:||2017||Publisher:||IMPACT JOURNALS LLC||Journal:||Oncotarget||Abstract:||
The Phosphatidylinositol 3-kinase (PI3Ks) pathway is commonly altereted in breast cancer patients, but its role is still unclear. Taselisib, a mutant PI3Kα selective inhibitor, and ipatasertib, an AKT inhibitor, are currently under investigation in clinical trials in combination with paclitaxel or hormonal therapies in breast cancer. The aim of this study was to evaluate if PI3K or AKT inhibition can prevent resistance to chemotherapy and potentiate its efficacy.
|Appears in Collections:||Articles|
Show full item record
checked on Nov 28, 2021
checked on Aug 31, 2020
WEB OF SCIENCETM
checked on Nov 24, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.